BMI's Executive Summary

[TOP]

The Sector At A Glance

Key Insights On The Pharmaceutical Sector Of Zimbabwe

The value of the Zimbabwean drug market has fallen dramatically since the mid-nineties and is now negligible. The collapse of the Zimbabwean dollar, the economic consequences of government policy and deteriorating relations with the international community has made Zimbabwe an extremely difficult location for drug manufacturers. Inflation is running at over 1,000% per year, while drug prices have increased by 1,376% since January 2005.

The Zimbabwe’s pharmaceutical market was estimated to be worth around US$5.2mn in 2005, with its value expected to dip further within the forecast period. Imports and exports will remain minimal due to the difficult economic situation in the country. In the meantime, foreign donations of drugs for HIV and other infective diseases will continue to distort the market trends. Over-the-counter (OTC) medicines and traditional treatments will gain prominence as pharmaceuticals become more unaffordable for the bulk of the population.

BMI’s adjusted Business Environment Rankings for the Middle East & Africa reveal that Zimbabwe is in 14th place. This is primarily due to the country’s dismal long-term political and economic environment. Rampant inflation and shortages of foreign currency have made domestic production difficult. Counterfeits are a major problem, and the situation is becoming even more severe as medicines are unaffordable for much of the population. Endemic corruption both in the health service and among government officials has also helped create a burgeoning black market.

Local drugmakers must rely on exports in order to generate enough foreign currency to survive. Domestic drugmaker CAPS Holdings, for example, sells drugs in a wide range of African markets. However, the company has recently lost its partner – Indian generics maker Shreya – in a local joint venture. Shreya is one of India’s leading ARV producers and its exit from the Zimbabwe, which has one of the highest HIV/AIDS caseloads in the world, is indicative of the challenging circumstances for even the most resilient of companies.

BMI's Country Pharmaceuticals and Healthcare Reports - Sample Contents Page

[TOP]

Chapter 1 - Executive Summary

Zimbabwe Pharmaceuticals & Healthcare Industry SWOT

Zimbabwe Political SWOT

Zimbabwe Economic SWOT

Zimbabwe Business Environment SWOT

Zimbabwe: Business Environment Ranking

Table: Business Environment Ranking: Middle East & Africa

Business Environment Ranking

Economics - Long-term Risk

Politics - Long-term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 2 - Zimbabwe: Market Summary

Chapter 3 - Regulatory Regime

Intellectual Property Developments

Pricing and Reimbursement Issues

Chapter 4 - Industry Developments

Healthcare System

Healthcare Funding

Healthcare Staff

Health Profile

Table: Key Health Indicators (WHO)

HIV/AIDS Crisis

Pharmaceutical Sector

HIV Manufacture Developments

Biotechnology Sector Developments

Impact of Foreign Currency Shortages

Chapter 5 - Industry Forecast Scenario

Overall Market Forecasts

Table: Zimbabwe Healthcare Data and Forecasts

Key Growth Factors – Industry

Table: Zimbabwe Pharmaceuticals Sector Historical Data & Forecasts

Key Growth Factors –Macroeconomic

Table: Economic Activity

Prescription Market Forecast

Table: Zimbabwe Prescription Drug Market Forecast

OTC Market Forecast

Table: Zimbabwe OTC Market Forecast

Generics and Branded Market Forecast

Table: Zimbabwe Generics and Branded Market Forecast

Export / Import Forecasts

Table: Zimbabwe Import / Domestic Market Forecast

Other Healthcare Data Forecasts

Table: Zimbabwe Other Healthcare forecast

Chapter 6 - Country Snapshot: Zimbabwe Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Chapter 7 - Competitive Landscape

Company Profiles

Ranbaxy

Datlabs

Varichem Laboratories

CAPS Holdings

Chapter 8 - BMI Forecast Modelling

How we generate our industry forecasts

Technical Process

Pharmaceutical Industry

Chapter 9 - Appendix: Regional Demographic Data

The Long View: Data Over The Economic Cycle (2000-2007)

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Competitive Landscape for Middle East & Africa Pharmaceuticals and Healthcare: Sample of Companies Ranked

[TOP]

Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.

Network of Middle Eastern and African Pharmaceutical & Healthcare Sources

[TOP]

BMI's Middle Eastern & African Pharmaceutical & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include: